EU-Moldova association deal may be scrapped if people say so — presidentWorld January 24, 23:10
NATO experts arrive in Moldova to assist in developing military strategyWorld January 24, 21:13
FIA F1 top management reshuffle unlikely to affect Russia’s Sochi GP — expertSport January 24, 20:42
Russia hopes for constructive work with Trump's administration at G20Business & Economy January 24, 20:29
Everything you need to know about Oscars 2017 nominationsSociety & Culture January 24, 19:57
Konchalovsky glad his film Paradise is absent from list of Oscar nomineesSociety & Culture January 24, 18:55
Russian meteorology service reports 2016 is record warm year in ArcticBusiness & Economy January 24, 18:22
Russian chief negotiator comments on outcome of Syria peace talks in AstanaRussian Politics & Diplomacy January 24, 18:11
Legendary Isinbayeva blasts recent German film on alleged doping in Russian athleticsSport January 24, 18:07
HAIFA, Israel /PRNewswire/ Sealantis Ltd., a private start-up, which develops alga-mimetic tissue adhesives, reports that it has received the CE Mark for Seal-V™, its vascular sealant. Seal-V™ is a protein-free bioresorbable sealant, intended to achieve hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels such as the carotid, femoral, brachial and iliac arteries.
Seal-V™ commences a new generation in tissue sealing. Being alga-mimetic it has an intrinsic ability to bind strongly to both native blood vessels and synthetic grafts, even in wet and moist conditions. In addition, the protein-free composition relieves Seal-V™ from risks associated with the use of protein-based products. Unlike hemostats, which are designed to cause blood to clot, Seal-V™ is not dependent on the presence of blood in order to be effective, and can be used as a prophylactic sealant.
"We are excited to be able to introduce Seal-V™ to the European market and to provide surgeons with a new and better option for controlling bleeding from suture-lines," says Mr. Tomer Fuchs, Sealantis CEO. Mr. Fuchs recently joined Sealantis, after serving over two decades in lead executive positions in global companies including Medtronic Ventor, Anorad and Vishay.
"Sealantis has been working closely with surgeons to leverage the extraordinary capabilities of its alga-mimetic technology and design products that will be strongly positioned in the multibillion dollars market of wound closure," says Dr. Zeev Gilkis, Sealantis Chairman.
In addition to Seal-V™, Sealantis has a pipeline of advanced solutions for a variety of clinical needs. Among them is a gastro-intestinal sealant, designed to prevent leakage of intestinal content from anastomoses, a potentially fatal complication of GI surgery; an adhesive for space obliteration in esthetic surgeries, which can significantly reduce the recovery time from face and body lifts and innovative combination devices for site-specific drug delivery.
Sealantis is currently working on strategic partnerships towards the coming market launch of Seal-V™.
About Sealantis Ltd.
Sealantis Ltd. is developing a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical leakage control, tissue adhesion and drug delivery. The Sealantis adhesives are protein-free, and have an extraordinary ability to adhere strongly to internal tissues even in wet environments. Sealantis was founded in 2007 by Prof. Havazelet Bianco-Peled, and is funded by the Alfred Mann Institute at the Technion (AMIT). Visit: http://www.sealantis.co.il